Legend Biotech Correlations

LEGN Stock  USD 49.58  0.51  1.04%   
The current 90-days correlation between Legend Biotech Corp and Amylyx Pharmaceuticals is -0.14 (i.e., Good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction.

Legend Biotech Correlation With Market

Weak diversification

The correlation between Legend Biotech Corp and DJI is 0.32 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Legend Biotech Corp and DJI in the same portfolio, assuming nothing else is changed.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Moving together with Legend Stock

  0.66NBIX Neurocrine BiosciencesPairCorr
  0.82PRLD Prelude TherapeuticsPairCorr
  0.67BDTX Black Diamond TherapPairCorr

Moving against Legend Stock

  0.63BHC Bausch Health CompaniesPairCorr
  0.45ZTS Zoetis IncPairCorr
  0.42GILD Gilead Sciences Sell-off TrendPairCorr
  0.42PAHC Phibro Animal HealthPairCorr
  0.39FHTX Foghorn TherapeuticsPairCorr
  0.35PHVS Pharvaris BVPairCorr
  0.51MMSI Merit Medical SystemsPairCorr
  0.41ICUI ICU MedicalPairCorr
  0.31RZLT RezolutePairCorr

Related Correlations Analysis

Please specify at least 3 valid symbols having historical data to build a meaningful correlation cloud. You can use symbol search above to locate your securities.

Legend Biotech Corporate Management

Elaine QianVP ResourcesProfile
James JDGeneral CounselProfile
Lori CPAChief OfficerProfile
Guowei FangChief DevelopmentProfile
Tina CarterCorporate LeadProfile
Steven GavelUS DevelopmentProfile
Marc HarrisonVP CounselProfile